296 related articles for article (PubMed ID: 27135245)
21. Pretreatment with betamethasone of patients with Graves' disease given radioiodine therapy: thyroid autoantibody responses and outcome of therapy.
Gamstedt A; Karlsson A
J Clin Endocrinol Metab; 1991 Jul; 73(1):125-31. PubMed ID: 2045463
[TBL] [Abstract][Full Text] [Related]
22. Management of overt and subclinical hypothyroidism. Factors influencing L-thyroxine dosage.
Rezzónico JN; Pusiol E; Saravi FD; Rezzónico M; Bossa N
Medicina (B Aires); 1999; 59(6):698-704. PubMed ID: 10752211
[TBL] [Abstract][Full Text] [Related]
23. Enhanced thyroid iodine metabolism in patients with triiodothyronine-predominant Graves' disease.
Takamatsu J; Hosoya T; Naito N; Yoshimura H; Kohno Y; Tarutani O; Kuma K; Sakane S; Takeda K; Mozai T
J Clin Endocrinol Metab; 1988 Jan; 66(1):147-52. PubMed ID: 3335601
[TBL] [Abstract][Full Text] [Related]
24. Hypothyroidism during antithyroid drug treatment with methimazole is a favorable prognostic indicator in patients with Graves' disease.
Choo YK; Yoo WS; Kim DW; Chung HK
Thyroid; 2010 Sep; 20(9):949-54. PubMed ID: 20629556
[TBL] [Abstract][Full Text] [Related]
25. Alterations of Global DNA Methylation and DNA Methyltransferase Expression in T and B Lymphocytes from Patients with Newly Diagnosed Autoimmune Thyroid Diseases After Treatment: A Follow-Up Study.
Guo Q; Wu D; Yu H; Bao J; Peng S; Shan Z; Guan H; Teng W
Thyroid; 2018 Mar; 28(3):377-385. PubMed ID: 29336230
[TBL] [Abstract][Full Text] [Related]
26. Discordant hypothyroxinemia and hypertriiodothyroninemia in treated patients with hyperthyroid Graves' disease.
Chen JJ; Ladenson PW
J Clin Endocrinol Metab; 1986 Jul; 63(1):102-6. PubMed ID: 2423547
[TBL] [Abstract][Full Text] [Related]
27. How selective are the new guidelines for treatment of subclinical hypothyroidism for patients with thyrotropin levels at or below 10 mIU/L?
Rosario PW; Calsolari MR
Thyroid; 2013 May; 23(5):562-5. PubMed ID: 23627903
[TBL] [Abstract][Full Text] [Related]
28. Serum thyrotropin-binding inhibiting immunoglobulin and thyroperoxidase antibody in Graves' hyperthyroidism after 131I therapy.
Hsu CH; Lee LS; Chang JJ; Liao ST; Chen SM; Hwang JY; Lo NI
J Formos Med Assoc; 1995; 94(1-2):5-9. PubMed ID: 7613234
[TBL] [Abstract][Full Text] [Related]
29. Transient high thyroid stimulating hormone and hypothyroidism incidence during follow up of subclinical hypothyroidism.
Abu-Helalah M; Alshraideh HA; Al-Sarayreh SA; Al-Hader A
Endocr Regul; 2021 Dec; 55(4):204-214. PubMed ID: 34879182
[No Abstract] [Full Text] [Related]
30. Ultrasonographic thyroid volume as a reliable prognostic index of radioiodine-131 treatment outcome in Graves' disease hyperthyroidism.
Gómez-Arnaiz N; Andía E; Gumà A; Abós R; Soler J; Gómez JM
Horm Metab Res; 2003 Aug; 35(8):492-7. PubMed ID: 12953167
[TBL] [Abstract][Full Text] [Related]
31. Clinical results of anti-inflammatory therapy in Graves' ophthalmopathy and association with thyroidal autoantibodies.
Eckstein AK; Plicht M; Lax H; Hirche H; Quadbeck B; Mann K; Steuhl KP; Esser J; Morgenthaler NG
Clin Endocrinol (Oxf); 2004 Nov; 61(5):612-8. PubMed ID: 15521965
[TBL] [Abstract][Full Text] [Related]
32. Does early administration of thyroxine reduce the development of Graves' ophthalmopathy after radioiodine treatment?
Tallstedt L; Lundell G; Blomgren H; Bring J
Eur J Endocrinol; 1994 May; 130(5):494-7. PubMed ID: 8180678
[TBL] [Abstract][Full Text] [Related]
33. [Clinical and immunological predictors of Graves' orbitopathy after radioiodine therapy of Graves' disease].
Sheremeta MS; Bessmertnaya EG; Elfimova AR; Babaeva DM; Belovalova IM; Sviridenko NY
Probl Endokrinol (Mosk); 2023 Nov; 69(5):16-24. PubMed ID: 37968948
[TBL] [Abstract][Full Text] [Related]
34. The prevalence of subclinical hypothyroidism in a pre-diabetes population and an analysis of related factors.
Chang X; Wang Y; Liu Y; Shen Y; Feng J; Liu Q; Jiang C; Yu J; Tang X; Jing G; Niu Q; Fu S
Ann Med; 2023 Dec; 55(1):643-651. PubMed ID: 37074323
[TBL] [Abstract][Full Text] [Related]
35. Continued suppression of serum TSH level may be attributed to TSH receptor antibody activity as well as the severity of thyrotoxicosis and the time to recovery of thyroid hormone in treated euthyroid Graves' patients.
Chung YJ; Lee BW; Kim JY; Jung JH; Min YK; Lee MS; Lee MK; Kim KW; Chung JH
Thyroid; 2006 Dec; 16(12):1251-7. PubMed ID: 17199435
[TBL] [Abstract][Full Text] [Related]
36. The incidence of ophthalmopathy after radioiodine therapy for Graves' disease: prognostic factors and the role of methimazole.
Kung AW; Yau CC; Cheng A
J Clin Endocrinol Metab; 1994 Aug; 79(2):542-6. PubMed ID: 7913934
[TBL] [Abstract][Full Text] [Related]
37. Abnormal TSH Prior to Surgery in Children with Graves' Disease Predicts Abnormal TSH Following Thyroidectomy.
Hazkani I; Stein E; Edwards E; Maddalozzo J; Johnston D; Samis J; Josefson J; Rastatter J
Laryngoscope; 2023 Sep; 133(9):2402-2406. PubMed ID: 36370147
[TBL] [Abstract][Full Text] [Related]
38. High thyroid-stimulating hormone level is associated with the risk of developing atherosclerosis in subclinical hypothyroidism.
Gao CX; Yang B; Guo Q; Wei LH; Tian LM
Horm Metab Res; 2015 Mar; 47(3):220-4. PubMed ID: 25372775
[TBL] [Abstract][Full Text] [Related]
39. Profile of Levothyroxine Replacement Therapy in Graves' Disease Patients with Hypothyroidism Post-Radioactive Iodine Ablation: Focus on Different Weight-Based Regimens.
Mathiphanit S; Yenseung N; Chatchomchuan W; Butadej S; Nakasatien S; Wanothayaroj E; Rajatanavin R; Himathongkam T; Thewjitcharoen Y
J ASEAN Fed Endocr Soc; 2022; 37(1):62-68. PubMed ID: 35800593
[TBL] [Abstract][Full Text] [Related]
40. Methimazole, but not betamethasone, prevents 131I treatment-induced rises in thyrotropin receptor autoantibodies in hyperthyroid Graves' disease.
Gamstedt A; Wadman B; Karlsson A
J Clin Endocrinol Metab; 1986 Apr; 62(4):773-7. PubMed ID: 2869050
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
